Department of Systems Medicine, University of Rome Tor Vergata, Rome, Italy.
Dipartimento Pediatrico Universitario Ospedaliero, IRCCS "Bambino Gesù" Children's Hospital, Rome, Italy.
Front Endocrinol (Lausanne). 2021 Dec 24;12:811846. doi: 10.3389/fendo.2021.811846. eCollection 2021.
Growth hormone (GH) therapy dates back to 1958 and, though has shown an excellent safety profile in the short-term, has never ceased to raise concern about potential long-term side effects. In the last decade, a number of observational studies in different cohorts of young adult patients treated with GH during childhood have yielded conflicting results. The attention has mainly focused on three major potential risks associated with GH therapy: cancer, cardio and cerebrovascular diseases and diabetes. This review intends to provide a detailed overview of the main studies reporting long-term safety in subjects treated with rhGH therapy during childhood, highlighting the evidence for or against the risk of cancer, cardio and cerebrovascular diseases and diabetes.
生长激素（GH）治疗可以追溯到 1958 年，尽管在短期内显示出了极好的安全性，但从未停止过对潜在长期副作用的关注。在过去的十年中，许多针对儿童期接受 GH 治疗的不同成年患者队列的观察性研究得出了相互矛盾的结果。人们主要关注与 GH 治疗相关的三个主要潜在风险：癌症、心血管疾病和糖尿病。这篇综述旨在详细概述报告儿童期接受 rhGH 治疗的受试者长期安全性的主要研究，重点介绍癌症、心血管疾病和糖尿病风险的证据。
